Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony L Cunningham

Showing results (191-200 of 208) with videos related to

Pageof 21
Sort By:
Journal of Leukocyte Biology|March 9, 2017
Phenotypic and functional consequences of different isolation protocols on skin mononuclear phagocytesRachel A Botting, Kirstie M Bertram, Heeva Baharlou, et al.
Plos Pathogens|April 27, 2021
Herpes Simplex Virus type 1 infects Langerhans cells and the novel epidermal dendritic cell, Epi-cDC2s, via different entry pathwaysKirstie M Bertram, Naomi R Truong, Jacinta B Smith, et al.
Frontiers in Immunology|September 27, 2021
Optimal Isolation Protocols for Examining and Interrogating Mononuclear Phagocytes From Human Intestinal TissueChloe M Doyle, Erica E Vine, Kirstie M Bertram, et al.
Human Vaccines & Immunotherapeutics|February 19, 2021
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trialsJoon Hyung Kim, John Diaz-Decaro, Ning Jiang, et al.
Plos Pathogens|June 26, 2024
Characterising plasmacytoid and myeloid AXL+ SIGLEC-6+ dendritic cell functions and their interactions with HIVFreja A Warner van Dijk, Orion Tong, Thomas R O'Neil, et al.
Eclinicalmedicine|July 9, 2025
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complicationsAna Strezova, Javier Díez Domingo, Anthony L Cunningham, et al.
The Journal of Clinical Investigation|February 8, 2022
The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cellsGabriel Duette, Bonnie Hiener, Hannah Morgan, et al.
The Journal of Infectious Diseases|March 13, 2018
Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or OlderAnthony L Cunningham, Thomas C Heineman, Himal Lal, et al.
Open Forum Infectious Diseases|June 5, 2026
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 YearsRafael Leon, Javier Diez-Domingo, Charles Andrews, et al.
Cell Reports|September 21, 2022
An in situ analysis pipeline for initial host-pathogen interactions reveals signatures of human colorectal HIV transmissionHeeva Baharlou, Nicolas Canete, Erica E Vine, et al.
Pageof 21

Showing results (191-200 of 208) with videos related to

Sort By:
Pageof 21
Journal of Leukocyte Biology|March 9, 2017
Phenotypic and functional consequences of different isolation protocols on skin mononuclear phagocytesRachel A Botting, Kirstie M Bertram, Heeva Baharlou, et al.
Plos Pathogens|April 27, 2021
Herpes Simplex Virus type 1 infects Langerhans cells and the novel epidermal dendritic cell, Epi-cDC2s, via different entry pathwaysKirstie M Bertram, Naomi R Truong, Jacinta B Smith, et al.
Frontiers in Immunology|September 27, 2021
Optimal Isolation Protocols for Examining and Interrogating Mononuclear Phagocytes From Human Intestinal TissueChloe M Doyle, Erica E Vine, Kirstie M Bertram, et al.
Human Vaccines & Immunotherapeutics|February 19, 2021
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trialsJoon Hyung Kim, John Diaz-Decaro, Ning Jiang, et al.
Plos Pathogens|June 26, 2024
Characterising plasmacytoid and myeloid AXL+ SIGLEC-6+ dendritic cell functions and their interactions with HIVFreja A Warner van Dijk, Orion Tong, Thomas R O'Neil, et al.
Eclinicalmedicine|July 9, 2025
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complicationsAna Strezova, Javier Díez Domingo, Anthony L Cunningham, et al.
The Journal of Clinical Investigation|February 8, 2022
The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cellsGabriel Duette, Bonnie Hiener, Hannah Morgan, et al.
The Journal of Infectious Diseases|March 13, 2018
Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or OlderAnthony L Cunningham, Thomas C Heineman, Himal Lal, et al.
Open Forum Infectious Diseases|June 5, 2026
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 YearsRafael Leon, Javier Diez-Domingo, Charles Andrews, et al.
Cell Reports|September 21, 2022
An in situ analysis pipeline for initial host-pathogen interactions reveals signatures of human colorectal HIV transmissionHeeva Baharlou, Nicolas Canete, Erica E Vine, et al.
Pageof 21